Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Bortezomib

Research Leaders

5 sponsors active, led by Fundación para la Investigación Biosanitaria del Principado de Asturias

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed2
Unknown1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05889312Recruiting

Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

NCT06284395UnknownPrimary

Two Schemes Response in Multiple Myeloma

NCT04838938Completed

Personalized Medicine in Patients With Infective Endocarditis

NCT05642117Completed

Pediatric Telephone Center Board 15

Showing all 4 trials

Research Network

Common Treatments

  • Bortezomib1
  • 18ffspg Petct In Nsclc1
  • 18ffspg Petct In Hnscc1

Active Sponsors

  • Fundación para la Investigación Biosanitaria del Principado de Asturias1
  • Guy's and St Thomas' NHS Foundation Trust1
  • King's College London1
  • University Hospital, Brest1
  • Hospital General de Mexico1

Top Investigators

Related Conditions

  • Emergencies1
  • Cancer1
  • Pediatric All1
  • Diagnosis1
  • Resistant Cancer1

Activity Timeline